Norbert Bischofberger hinted on the most recent quarterly CC that GILD would run a 16w trial of Sofa + ribavirin in genotype-3. The inclusion of genotype-1 is a mild surprise, as oc631 noted.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”